VivoSeq
Other

Prophylaxis

1

Pipeline Programs

39

Active Trials

17

Companies Involved

Prophylaxis is an early-stage landscape with 1 program across 17 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Acacia Pharma Ltd, Bayer.

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

32/100

Mech. Concentration

100/100

Completion Rate

82/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Trial Status

232

clinical trials

Completed134 · 58%
Unknown status29 · 13%
Recruiting25 · 11%
Terminated17 · 7%
Withdrawn13 · 6%
Not yet recruiting6 · 3%
Other8 · 3%

Trial Activity

232 trials

Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)
Recruiting··N/A·NCT04762134·560 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)